512 Stock Overview
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
Grand Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$4.42|
|52 Week High||HK$7.40|
|52 Week Low||HK$3.99|
|1 Month Change||3.76%|
|3 Month Change||-22.18%|
|1 Year Change||-38.27%|
|3 Year Change||-0.67%|
|5 Year Change||115.61%|
|Change since IPO||-83.00%|
Recent News & Updates
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
The board of Grand Pharmaceutical Group Limited ( HKG:512 ) has announced that it will pay a dividend on the 21st of...
|512||HK Pharmaceuticals||HK Market|
Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned -45.3% over the past year.
Return vs Market: 512 underperformed the Hong Kong Market which returned -23.8% over the past year.
|512 Average Weekly Movement||5.0%|
|Pharmaceuticals Industry Average Movement||6.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.6%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 512 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 512's weekly volatility (5%) has been stable over the past year.
About the Company
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices.
Grand Pharmaceutical Group Fundamentals Summary
|512 fundamental statistics|
Is 512 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|512 income statement (TTM)|
|Cost of Revenue||HK$3.35b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.68|
|Net Profit Margin||27.94%|
How did 512 perform over the long term?See historical performance and comparison
2.5%Current Dividend Yield
Is 512 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 512?
Other financial metrics that can be useful for relative valuation.
|What is 512's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 512's PE Ratio compare to its peers?
|512 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 512 is good value based on its Price-To-Earnings Ratio (6.5x) compared to the peer average (11.8x).
Price to Earnings Ratio vs Industry
How does 512's PE Ratio compare vs other companies in the Hong Kong Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 512 is good value based on its Price-To-Earnings Ratio (6.5x) compared to the Hong Kong Pharmaceuticals industry average (9.4x)
Price to Earnings Ratio vs Fair Ratio
What is 512's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||6.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 512's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 512 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 512 (HK$4.42) is trading below our estimate of fair value (HK$9.08)
Significantly Below Fair Value: 512 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 512's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Grand Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 512's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if 512's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 512's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 512's revenue (18.7% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 512's revenue (18.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 512's Return on Equity is forecast to be low in 3 years time (15%).
Discover growth companies
How has Grand Pharmaceutical Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 512 has a large one-off gain of HK$516.8M impacting its December 31 2021 financial results.
Growing Profit Margin: 512's current net profit margins (27.9%) are lower than last year (28.2%).
Past Earnings Growth Analysis
Earnings Trend: 512's earnings have grown significantly by 40.1% per year over the past 5 years.
Accelerating Growth: 512's earnings growth over the past year (34%) is below its 5-year average (40.1% per year).
Earnings vs Industry: 512 earnings growth over the past year (34%) exceeded the Pharmaceuticals industry 16.1%.
Return on Equity
High ROE: 512's Return on Equity (17.9%) is considered low.
Discover strong past performing companies
How is Grand Pharmaceutical Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 512's short term assets (HK$6.8B) exceed its short term liabilities (HK$5.6B).
Long Term Liabilities: 512's short term assets (HK$6.8B) exceed its long term liabilities (HK$2.0B).
Debt to Equity History and Analysis
Debt Level: 512's net debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: 512's debt to equity ratio has reduced from 141% to 27.1% over the past 5 years.
Debt Coverage: 512's debt is well covered by operating cash flow (55.1%).
Interest Coverage: 512's interest payments on its debt are well covered by EBIT (121.1x coverage).
Discover healthy companies
What is Grand Pharmaceutical Group current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 512's dividend (2.49%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.78%).
High Dividend: 512's dividend (2.49%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.91%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 512 has been paying a dividend for less than 10 years.
Growing Dividend: 512's dividend payments have increased, but the company has only paid a dividend for 3 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (16.2%), 512's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (26.4%), 512's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chao Zhou (31 yo)
Mr. Chao Zhou serves as Executive Deputy Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since April 2019 and serves as its Chie...
Experienced Management: 512's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: 512's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 512 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Grand Pharmaceutical Group Limited's employee growth, exchange listings and data sources
- Name: Grand Pharmaceutical Group Limited
- Ticker: 512
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$15.484b
- Shares outstanding: 3.53b
- Website: https://www.grandpharm.com
Number of Employees
- Grand Pharmaceutical Group Limited
- The Center
- 33rd Floor
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/23 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.